262 related articles for article (PubMed ID: 34769156)
1. Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.
Jazirehi AR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769156
[TBL] [Abstract][Full Text] [Related]
2. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
3. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
5. T-cell receptor gene therapy of established tumors in a murine melanoma model.
Abad JD; Wrzensinski C; Overwijk W; De Witte MA; Jorritsma A; Hsu C; Gattinoni L; Cohen CJ; Paulos CM; Palmer DC; Haanen JB; Schumacher TN; Rosenberg SA; Restifo NP; Morgan RA
J Immunother; 2008 Jan; 31(1):1-6. PubMed ID: 18157006
[TBL] [Abstract][Full Text] [Related]
6. Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
Bobisse S; Rondina M; Merlo A; Tisato V; Mandruzzato S; Amendola M; Naldini L; Willemsen RA; Debets R; Zanovello P; Rosato A
Cancer Res; 2009 Dec; 69(24):9385-94. PubMed ID: 19996290
[TBL] [Abstract][Full Text] [Related]
7. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
8. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
9. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
Koya RC; Mok S; Otte N; Blacketor KJ; Comin-Anduix B; Tumeh PC; Minasyan A; Graham NA; Graeber TG; Chodon T; Ribas A
Cancer Res; 2012 Aug; 72(16):3928-37. PubMed ID: 22693252
[TBL] [Abstract][Full Text] [Related]
10. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer.
Parlar A; Sayitoglu EC; Ozkazanc D; Georgoudaki AM; Pamukcu C; Aras M; Josey BJ; Chrobok M; Branecki S; Zahedimaram P; Ikromzoda L; Alici E; Erman B; Duru AD; Sutlu T
Eur J Immunol; 2019 Aug; 49(8):1278-1290. PubMed ID: 31054264
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.
Chodon T; Comin-Anduix B; Chmielowski B; Koya RC; Wu Z; Auerbach M; Ng C; Avramis E; Seja E; Villanueva A; McCannel TA; Ishiyama A; Czernin J; Radu CG; Wang X; Gjertson DW; Cochran AJ; Cornetta K; Wong DJ; Kaplan-Lefko P; Hamid O; Samlowski W; Cohen PA; Daniels GA; Mukherji B; Yang L; Zack JA; Kohn DB; Heath JR; Glaspy JA; Witte ON; Baltimore D; Economou JS; Ribas A
Clin Cancer Res; 2014 May; 20(9):2457-65. PubMed ID: 24634374
[TBL] [Abstract][Full Text] [Related]
12. An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells.
Knies D; Klobuch S; Xue SA; Birtel M; Echchannaoui H; Yildiz O; Omokoko T; Guillaume P; Romero P; Stauss H; Sahin U; Herr W; Theobald M; Thomas S; Voss RH
Oncotarget; 2016 Apr; 7(16):21199-221. PubMed ID: 27028870
[TBL] [Abstract][Full Text] [Related]
13. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
14. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.
Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA
Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115
[TBL] [Abstract][Full Text] [Related]
15. Coexpression of the T-cell receptor constant alpha domain triggers tumor reactivity of single-chain TCR-transduced human T cells.
Voss RH; Thomas S; Pfirschke C; Hauptrock B; Klobuch S; Kuball J; Grabowski M; Engel R; Guillaume P; Romero P; Huber C; Beckhove P; Theobald M
Blood; 2010 Jun; 115(25):5154-63. PubMed ID: 20378753
[TBL] [Abstract][Full Text] [Related]
16. T-cell receptor gene therapy in human melanoma-bearing immune-deficient mice: human but not mouse T cells recapitulate outcome of clinical studies.
Straetemans T; Coccoris M; Berrevoets C; Treffers-Westerlaken E; Scholten CE; Schipper D; Ten Hagen TL; Debets R
Hum Gene Ther; 2012 Feb; 23(2):187-201. PubMed ID: 21958294
[TBL] [Abstract][Full Text] [Related]
17. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor T Cell Therapy in Hematology.
Ataca P; Arslan Ö
Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
[TBL] [Abstract][Full Text] [Related]
19. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
[TBL] [Abstract][Full Text] [Related]
20. TCR Analyses of Two Vast and Shared Melanoma Antigen-Specific T Cell Repertoires: Common and Specific Features.
Simon S; Wu Z; Cruard J; Vignard V; Fortun A; Khammari A; Dreno B; Lang F; Rulli SJ; Labarriere N
Front Immunol; 2018; 9():1962. PubMed ID: 30214446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]